113 related articles for article (PubMed ID: 33027479)
1. BODY COMPOSITION IMPACT ON SURVIVAL AND TOXICITY OF TREATMENT IN PANCREATIC CANCER: CROSS-SECTIONAL PILOT STUDY.
BarrÈre APN; Piovacari SMF; UsÓn Junior PLS; Gansl RC; Pereira AZ; Hamerschlak N
Arq Gastroenterol; 2020; 57(3):278-282. PubMed ID: 33027479
[TBL] [Abstract][Full Text] [Related]
2. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
3. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
5. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.
Fujiwara N; Nakagawa H; Kudo Y; Tateishi R; Taguri M; Watadani T; Nakagomi R; Kondo M; Nakatsuka T; Minami T; Sato M; Uchino K; Enooku K; Kondo Y; Asaoka Y; Tanaka Y; Ohtomo K; Shiina S; Koike K
J Hepatol; 2015 Jul; 63(1):131-40. PubMed ID: 25724366
[TBL] [Abstract][Full Text] [Related]
7. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
8. Comparing Western and Eastern criteria for sarcopenia and their association with survival in patients with pancreatic cancer.
Wu CH; Chang MC; Lyadov VK; Liang PC; Chen CM; Shih TT; Chang YT
Clin Nutr; 2019 Apr; 38(2):862-869. PubMed ID: 29503056
[TBL] [Abstract][Full Text] [Related]
9. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer.
van Dijk DP; Bakens MJ; Coolsen MM; Rensen SS; van Dam RM; Bours MJ; Weijenberg MP; Dejong CH; Olde Damink SW
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):317-326. PubMed ID: 27897432
[TBL] [Abstract][Full Text] [Related]
10. Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer.
Okumura S; Kaido T; Hamaguchi Y; Kobayashi A; Shirai H; Yao S; Yagi S; Kamo N; Hatano E; Okajima H; Takaori K; Uemoto S
Ann Surg Oncol; 2017 Nov; 24(12):3732-3740. PubMed ID: 28871520
[TBL] [Abstract][Full Text] [Related]
11. Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer.
Lee J; Lee JC; Kim HW; Kim J; Hwang JH
PLoS One; 2020; 15(9):e0238649. PubMed ID: 32936836
[TBL] [Abstract][Full Text] [Related]
12. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study.
Dalal S; Hui D; Bidaut L; Lem K; Del Fabbro E; Crane C; Reyes-Gibby CC; Bedi D; Bruera E
J Pain Symptom Manage; 2012 Aug; 44(2):181-91. PubMed ID: 22695045
[TBL] [Abstract][Full Text] [Related]
13. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
14. Can pancreatic cancer behavior be predicted based on computed tomography measurements of fat and muscle mass?
Clark W; Swaid F; Luberice K; Bowman TA; Downs D; Ross SB; Rosemurgy AS
Int J Surg Oncol (N Y); 2016 Dec; 1(2):e04. PubMed ID: 29177207
[TBL] [Abstract][Full Text] [Related]
15. Artificial intelligence to assess body composition on routine abdominal CT scans and predict mortality in pancreatic cancer- A recipe for your local application.
Hsu TH; Schawkat K; Berkowitz SJ; Wei JL; Makoyeva A; Legare K; DeCicco C; Paez SN; Wu JSH; Szolovits P; Kikinis R; Moser AJ; Goehler A
Eur J Radiol; 2021 Sep; 142():109834. PubMed ID: 34252866
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
Charette N; Vandeputte C; Ameye L; Bogaert CV; Krygier J; Guiot T; Deleporte A; Delaunoit T; Geboes K; Van Laethem JL; Peeters M; Demolin G; Holbrechts S; Flamen P; Paesmans M; Hendlisz A
BMC Cancer; 2019 Feb; 19(1):134. PubMed ID: 30744591
[TBL] [Abstract][Full Text] [Related]
17. Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
Park HS; Kim HS; Beom SH; Rha SY; Chung HC; Kim JH; Chun YJ; Lee SW; Choe EA; Heo SJ; Noh SH; Hyung WJ; Cheong JH; Kim HI; Son T; Lim JS; Baek SE; Jung M
Ann Surg Oncol; 2018 Oct; 25(11):3222-3230. PubMed ID: 30051367
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Franzoi MA; Vandeputte C; Eiger D; Caparica R; Brandão M; De Angelis C; Hendlisz A; Awada A; Piccart M; de Azambuja E
Breast Cancer Res Treat; 2020 May; 181(1):199-209. PubMed ID: 32246377
[TBL] [Abstract][Full Text] [Related]
19. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.
Caan BJ; Cespedes Feliciano EM; Prado CM; Alexeeff S; Kroenke CH; Bradshaw P; Quesenberry CP; Weltzien EK; Castillo AL; Olobatuyi TA; Chen WY
JAMA Oncol; 2018 Jun; 4(6):798-804. PubMed ID: 29621380
[TBL] [Abstract][Full Text] [Related]
20. Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment.
Hagens ERC; Feenstra ML; van Egmond MA; van Laarhoven HWM; Hulshof MCCM; Boshier PR; Low DE; van Berge Henegouwen MI; Gisbertz SS
J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):756-767. PubMed ID: 32096923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
